Revenue and Operating Income Grew Year-Over-Year by 68% and 28%, Respectively
PLAINVIEW, NY / ACCESSWIRE / August 15, 2016 / Vasomedical, Inc. (“Vasomedical”) (OTC PK: VASO) today reported its operating results for the three months ended June 30, 2016.
“We are pleased to report that the Company recorded $18.2 million of total revenue during the second quarter of 2016, a 68% increase from the same quarter a year ago, due mainly to the inclusion of the NetWolves operations we acquired at the end of May 2015 as well as the growth in the healthcare IT VAR (value added resale) business we started in late 2014. Our proprietary equipment business unit also saw significant growth and improvement during the quarter,” commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “Adjusted EBITDA was $886 thousand and $1.6 million for the three- and six-month period ending June 30, respectively, compared to $751 thousand and $729 thousand for the same periods last year, representing a growth of 18% and 119% year-over-year. We also recorded improvement in net income for the second quarter and first half of 2016. Given this momentum as well as our historical trend of being more profitable in the second half of the year, we feel confident in delivering the third consecutive year of profitability in 2016.”
“It is exciting to see significant revenue growth from our healthcare IT VAR operations in the second quarter of 2016. Moreover, the substantial backlog in this business unit continues to grow, and our team is working hard to turn it into revenue and profit as we accelerate the implementation of the underlying IT services for the customers,” concluded Dr. Ma.
Three Months Ended June 30, 2016 Financial Results
For the three months ended June 30, 2016, revenue increased by 68% to $18.2 million from $10.8 million for the same period of 2015. This is primarily attributable to an increase of $7.3 million of revenue in our IT segment, $6.5 million of which was from the NetWolves subsidiary the Company acquired in the end of May 2015, and an increase of $841 thousand, or 1781%, in our healthcare IT VAR business. Additionally, equipment segment revenue increased 23% to $1.2 million.
Gross profit for the second quarter of 2016 increased 38% to $10.1 million, compared with $7.3 million for the second quarter of 2015. The increase was principally due to the increase of $2.8 million in the IT segment, including $2.7 million from our NetWolves operations, and an increase of $258 thousand in our equipment segment, offset by a slightly lower gross profit in our professional sales services segment.
Selling, general and administrative (SG&A) expenses for the second quarter of 2016 increased to $9.7 million from $7.0 million for the second quarter last year. The increase is primarily due to including three months of the NetWolves operations in the quarter, compared to only one month of NetWolves operations for the second quarter 2015.
Operating income for the second quarter 2016 was $264 thousand, compared to $206 thousand for the same period in 2015, representing an increase of 28%. The improvement in operating income was due to the increase in gross profit and lower SG&A expenses relative to revenue. SG&A expenses were 53% of revenues for the quarter ended June 30, 2016, compared to 64% of revenues for the same period in 2015. Net income for the three months ended June 30, 2016 was $213 thousand, compared with net income of $191 thousand for the three months ended June 30, 2015, an increase of 12%.
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation) rose to $0.9 million for the three months ended June 30, 2016, compared to $0.8 million for the same period a year ago, representing an increase of 18%.
Net cash generated from operating activities in the first half of 2016 was $3.7 million. As of June 30, 2016, the Company had cash and cash equivalents of approximately $5.6 million, compared to cash and cash equivalents of $2.2 million at December 31, 2015. We anticipate continued positive cash flows from operations for the remainder of the year.
Conference Call Information
The Company will host a conference call on Monday, August 15, 2016 at 11:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedical. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033 internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, http://www.vasomedical.com/. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
Link to Yahoo Finance: http://finance.yahoo.com/news/vasomedical-announces-second-quarter-2016-130000857.html
Management to Hold Investor Conference Call on August 15, 2016 at 11:00 a.m. ET
PLAINVIEW, NY / ACCESSWIRE / August 8, 2016 / Vasomedical, Inc. (PINKSHEETS:VASO) announced today that it will release its financial results for the three months ended June 30, 2016 on Monday, August 15, 2016, before market open.
The Company will host a conference call on Monday, August 15, 2016 at 11:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedical. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033, internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, www.vasomedical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available at www.vasomedical.com approximately two hours after completion of the live conference call. To access the replay of the call, which will be available until September 15, 2016, please dial 1-877-660-6853 or 1-201-612-7415, use the code 13643094.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products and healthcare software solutions as well as in the provision of managed network services. The Company conducts its business through four wholly owned subsidiaries as follows. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC, a managed network services provider with an extensive proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations. Vasomedical Global Corp. operates the Company’s China-based subsidiaries. Additional information is available on the Company’s website at www.vasomedical.com.
Investor Contacts:
Michael Beecher / Amanda Jiang Investor Relations
516-508-5805
mbeecher@vasomedical.com / ajiang@vasomedical.com
SOURCE: Vasomedical, Inc.
Link to Yahoo Finance: http://finance.yahoo.com/news/vasomedical-report-second-quarter-2016-130000564.html
Revenue Grew 135% Year-over-Year; Adjusted EBITDA Improved to $0.71 Million
PLAINVIEW, NY / ACCESSWIRE / May 13, 2016 / Vasomedical, Inc. (“Vasomedical”) (OTC PK: VASO) today reported its operating results for the three months ended March 31, 2016.
“We are excited to report that during the first quarter 2016, the Company recorded $17.5 million of revenue, a 135% increase compared to the same quarter a year ago, mainly as a result of including $9.2 million from the NetWolves operations we acquired at the end of May 2015. Adjusted EBITDA was $0.71 million compared to a negative adjusted EBITDA of $0.02 million in the first quarter 2015, representing an improvement of $0.73 million,” commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “While we usually incur a loss for the beginning part of the fiscal year due to the seasonality of our business, our net loss for the first quarter was reduced again this year, to only $0.10 million. Given this momentum, we expect to continue profitability on an annual basis in 2016.”
“We also booked $0.49 million of revenue from our healthcare IT VAR operations in the first quarter of 2016, compared to no revenue in the first quarter of 2015. We have built a substantial backlog in our IT VAR operations and anticipate significant revenue growth from this business for the full year,” concluded Dr. Ma.
Three Months Ended March 31, 2016 Financial Results
For the three months ended March 31, 2016, revenue increased by 135% to $17.5 million from $7.5 million for the same period of 2015. This is mainly attributable to $9.7 million of revenue from our IT segment, $9.2 million of which was from the NetWolves subsidiary the Company acquired in May 2015, and an increase of $456 thousand, or 7%, in our professional sales services segment.
Gross profit for the first quarter of 2016 increased 80% to $10.0 million, compared with $5.6 million for the first quarter of 2015. The increase was principally due to the increase of $4.0 million in the IT segment, including $3.9 million from our NetWolves operations, and an increase of $568 thousand in our professional sales services segment.
Selling, general and administrative (SG&A) expenses for the first quarter of 2016 increased to $9.7 million from $5.7 million for the first quarter last year. The increase is primarily due to including the NetWolves operations in the quarter.
Operating income for the first quarter 2016 was $159 thousand, compared to an operating loss of $286 thousand for the same period in 2015. The improvement in operating income was due to the increase in gross profit and lower SG&A expenses relative to revenue. SG&A expenses were 55% of revenues for the quarter ended March 31, 2016, compared to 77% of revenues for the same period in 2015. Net loss for the three months ended March 31, 2016 was $104 thousand, compared with a net loss of $252 thousand for the three months ended March 31, 2015.
Net cash generated from operating activities in the first quarter of 2016 was $1.9 million. As of March 31, 2016, the Company had cash and cash equivalents of approximately $4.7 million, compared to cash and cash equivalents of $2.2 million at December 31, 2015. We anticipate continued positive cash flows from operations for the remainder of the year.
Conference Call Information
The Company will host a conference call on Friday, May 13, 2016 at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedical. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033 internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, http://www.vasomedical.com/. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.vasomedical.com/. To access the dial-in replay of the call, which will be available until June 13, 2016, please dial 1-877-660-6853 or 1-201-612-7415. All dial-in participants must use the following code to access the call: 13637214.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company with several distinctive but related specialties: professional sales services for diagnostic imaging products; managed IT systems and services, including healthcare software solutions and network connectivity services; and design, manufacture and sale of proprietary medical devices.
Vasomedical operates through four wholly owned subsidiaries. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare (www.vasohealthcare.com), provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC (www.netwolves.com), a managed network services provider with an extensive, proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. (www.vasosolutions.com), manages and coordinates the design, manufacture and sales of EECP® Therapy Systems and other medical equipment operations. Vasomedical Global Corp. (www.vasoglobal.com), operates the Company’s China-based subsidiaries, including Biox Instruments Co. Ltd. and Life Enhancement Technology Limited. It is also the minority shareholder of VSK Medical Limited, a marketing and sales company for ECP products in the international market. Additional information is available on the Company’s website at www.vasomedical.com.
Summarized Financial Information
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “plans,” “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreements; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Michael J. Beecher / Amanda Jiang
Investor Relations
Phone: 516-508-5840
Email: mbeecher@vasomedical.com / ajiang@vasomedical.com
SOURCE: Vasomedical, Inc.
Link to Accesswire: https://www.accesswire.com/439947/Vasomedical-Announces-First-Quarter-2016-Financial-Results
Management to Hold Investor Conference Call on May 13, 2016 at 10:00 a.m. ET
PLAINVIEW, NY / ACCESSWIRE / May 6, 2016 / Vasomedical, Inc. (PINKSHEETS: VASO) announced today that it will release its financial results for the three months ended March 31, 2016 on Friday, May 13, 2016, before market open.
The Company will host a conference call on Friday, May 13, 2016 at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedical. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033, internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, www.vasomedical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available at www.vasomedical.com approximately two hours after completion of the live conference call. To access the replay of the call, which will be available until June 13, 2016, please dial 1-877-660-6853 or 1-201-612-7415, use the code 13637214.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products and healthcare software solutions as well as in the provision of managed network services. The Company conducts its business through four wholly owned subsidiaries as follows. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC, a managed network services provider with an extensive proprietary service platform to a broad base of customers. Vasomedical Solutions, Inc. manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations. Vasomedical Global Corp. operates the Company’s China-based subsidiaries. Additional information is available on the Company’s website at www.vasomedical.com.
Investor Contacts:
Michael Beecher / Amanda Jiang
Investor Relations
516-508-5805
mbeecher@vasomedical.com / ajiang@vasomedical.com
SOURCE: Vasomedical, Inc.
Link to Yahoo Finance: http://finance.yahoo.com/news/vasomedical-report-first-quarter-2016-130000291.html
Net Income Increased 239% to $3.8 Million; Adjusted EBITDA Increased 205% to $5.8 Million on Record Revenue
PLAINVIEW, NY / ACCESSWIRE / March 29, 2016 / Vasomedical, Inc. (“Vasomedical”) (OTC PK: VASO) today reported its operating results for the three months and year ended December 31, 2015.
“With a 63% year-over-year growth in annual revenue to a record $57.1 million, including revenue of $20.7 million from seven months of NetWolves operations, we are excited to report a net income of $3.8 million for fiscal year 2015, an increase of 239% from $1.1 million reported for the prior year,” stated Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “Our VasoHealthcare subsidiary continued to be a successful and most significant contributor to our financial results in 2015, and our VasoTechnology division began to play an important role in our total revenue during the year, while performance in our proprietary equipment business also improved for 2015, especially in the international market. Further, our operations generated positive cash flow of $6.5 million in 2015, substantially strengthening the Company’s financial position with cash balances of approximately $5 million as of March 25, 2016.”
“The year 2015 represented another milestone as we not only saw great growth in the top- and bottom-line numbers, we have also built our Company into a robust enterprise with a diversified revenue stream, with approximately 44%, 50% and 6% of revenue in 2015 from our professional sales services, IT and equipment segments, respectively, on an annualized basis. We expect continued revenue growth and profitability in 2016 as our growth strategy continues to show positive results. We remain optimistic of the outlook for NetWolves and the value added reseller business for the GEHC IT solutions, and look forward to significant progress in this IT segment,” concluded Dr. Ma.
Financial Results for Three Months Ended December 31, 2015
For the three months ended December 31, 2015, revenue increased 73.1% to $21.4 million from $12.4 million for the same period of 2014. This is primarily attributable to the inclusion of $9.2 million of revenue from the NetWolves operations in the fourth quarter 2015, offset by a small decrease in revenues from our professional sales services and equipment segments.
Gross profit for the fourth quarter of 2015 increased 37.6% to $12.6 million, compared with a gross profit of $9.2 million for the fourth quarter of 2014. This increase is primarily a result of revenue from our NetWolves subsidiary as noted above, offset by a decrease in gross profit in our equipment segment.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2015 increased 52.6% to $9.9 million compared to $6.5 million for the fourth quarter of 2014. The increase is primarily attributable to including SG&A costs from the NetWolves operations, offset by a decrease in expenses in our professional sales services and equipment segments. SG&A expenses were 46.1% of revenue in the fourth quarter 2015 compared to 52.3% of revenue for the same quarter of 2014.
Net income for the three months ended December 31, 2015 was $2.7 million, compared with a net income of $2.5 million for the three months ended December 31, 2014.
Financial Results for Year Ended December 31, 2015
For the year ended December 31, 2015, revenue increased $22.1 million, or 63.3%, to $57.1 million, compared with $35.0 million for the year 2014. Commission revenues in our professional sales services segment increased by 4.5% to $31.6 million for the year 2015, as compared with $30.2 million for the prior year. The increase was due primarily to higher installations of underlying equipment by GEHC in 2015, offset by lower commission rates for the equipment installed in 2015. Revenue in our IT segment was $21.1 million for the year ended December 31, 2015, compared to revenue of $48 thousand in 2014, mainly as a result of including $20.7 million of revenue from NetWolves in 2015. Equipment segment revenue for the year 2015 decreased by 7% to $4.3 million, compared to $4.7 million in 2014, principally due to a decrease in volume from EECP® sales.
Gross profit for the year ended December 31, 2015 increased 40.4% to $35.4 million, from $25.2 million in 2014. This increase is due primarily to $8.5 million of gross profit from NetWolves and to higher revenue in the professional sales services segment as noted above.
Link to Yahoo Finance: http://finance.yahoo.com/news/vasomedical-announces-financial-results-fourth-130000531.html
© 2024 Vaso Corporation | Terms of Service | Privacy Policy
